1
|
Honetschlägerová Z, Husková Z, Kikerlová S, Sadowski J, Kompanowska-Jezierska E, Táborský M, Vaňourková Z, Kujal P, Červenka L. Renal sympathetic denervation improves pressure-natriuresis relationship in cardiorenal syndrome: insight from studies with Ren-2 transgenic hypertensive rats with volume overload induced using aorto-caval fistula. Hypertens Res 2024; 47:998-1016. [PMID: 38302775 PMCID: PMC10994851 DOI: 10.1038/s41440-024-01583-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Revised: 12/20/2023] [Accepted: 12/24/2023] [Indexed: 02/03/2024]
Abstract
The aim was to evaluate the effects of renal denervation (RDN) on autoregulation of renal hemodynamics and the pressure-natriuresis relationship in Ren-2 transgenic rats (TGR) with aorto-caval fistula (ACF)-induced heart failure (HF). RDN was performed one week after creation of ACF or sham-operation. Animals were prepared for evaluation of autoregulatory capacity of renal blood flow (RBF) and glomerular filtration rate (GFR), and of the pressure-natriuresis characteristics after stepwise changes in renal arterial pressure (RAP) induced by aortic clamping. Their basal values of blood pressure and renal function were significantly lower than with innervated sham-operated TGR (p < 0.05 in all cases): mean arterial pressure (MAP) (115 ± 2 vs. 160 ± 3 mmHg), RBF (6.91 ± 0.33 vs. 10.87 ± 0.38 ml.min-1.g-1), urine flow (UF) (11.3 ± 1.79 vs. 43.17 ± 3.24 µl.min-1.g-1) and absolute sodium excretion (UNaV) (1.08 ± 0.27 vs, 6.38 ± 0.76 µmol.min-1.g-1). After denervation ACF TGR showed improved autoregulation of RBF: at lowest RAP level (80 mmHg) the value was higher than in innervated ACF TGR (6.92 ± 0.26 vs. 4.54 ± 0.22 ml.min-1.g-1, p < 0.05). Also, the pressure-natriuresis relationship was markedly improved after RDN: at the RAP of 80 mmHg UF equaled 4.31 ± 0.99 vs. 0.26 ± 0.09 µl.min-1.g-1 recorded in innervated ACF TGR, UNaV was 0.31 ± 0.05 vs. 0.04 ± 0.01 µmol min-1.g-1 (p < 0.05 in all cases). In conclusion, in our model of hypertensive rat with ACF-induced HF, RDN improved autoregulatory capacity of RBF and the pressure-natriuresis relationship when measured at the stage of HF decompensation.
Collapse
Affiliation(s)
- Zuzana Honetschlägerová
- Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - Zuzana Husková
- Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - Soňa Kikerlová
- Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - Janusz Sadowski
- Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
| | - Elzbieta Kompanowska-Jezierska
- Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
| | - Miloš Táborský
- Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic
| | - Zdenka Vaňourková
- Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - Petr Kujal
- Department of Pathology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Luděk Červenka
- Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic.
| |
Collapse
|
2
|
Honetschlägerová Z, Sadowski J, Kompanowska-Jezierska E, Maxová H, Táborský M, Kujal P, Červenka L. Impaired renal autoregulation and pressure-natriuresis: any role in the development of heart failure in normotensive and angiotensin II-dependent hypertensive rats? Hypertens Res 2023; 46:2340-2355. [PMID: 37592042 PMCID: PMC10550820 DOI: 10.1038/s41440-023-01401-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 06/30/2023] [Accepted: 07/28/2023] [Indexed: 08/19/2023]
Abstract
The aim of the present study was to assess the autoregulatory capacity of renal blood flow (RBF) and of the pressure-natriuresis characteristics in the early phase of heart failure (HF) in rats, normotensive and with angiotensin II (ANG II)-dependent hypertension. Ren-2 transgenic rats (TGR) were employed as a model of ANG II-dependent hypertension. HF was induced by creating the aorto-caval fistula (ACF). One week after ACF creation or sham-operation, the animals were prepared for studies evaluating in vivo RBF autoregulatory capacity and the pressure-natriuresis characteristics after stepwise changes in renal arterial pressure (RAP) induced by aortic clamping. In ACF TGR the basal mean arterial pressure, RBF, urine flow (UF), and absolute sodium excretion (UNaV) were all significantly lower tha n in sham-operated TGR. In the latter, reductions in renal arterial pressure (RAP) significantly decreased RBF whereas in ACF TGR they did not change. Stepwise reductions in RAP resulted in marked decreases in UF and UNaV in sham-operated as well as in ACF TGR, however, these decreases were significantly greater in the former. Our data show that compared with sham-operated TGR, ACF TGR displayed well-maintained RBF autoregulatory capacity and improved slope of the pressure-natriuresis relationship. Thus, even though in the very early HF stage renal dysfunction was demonstrable, in the HF model of ANG II-dependent hypertensive rat such dysfunction and the subsequent HF decompensation cannot be simply ascribed to impaired renal autoregulation and pressure-natriuresis relationship.
Collapse
Affiliation(s)
- Zuzana Honetschlägerová
- Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
| | - Janusz Sadowski
- Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
| | - Elzbieta Kompanowska-Jezierska
- Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
| | - Hana Maxová
- Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Miloš Táborský
- Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic
| | - Petr Kujal
- Department of Pathology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Luděk Červenka
- Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic
| |
Collapse
|
5
|
Bishara B, Abu-Saleh N, Awad H, Ghrayeb N, Goltsman I, Aronson D, Khamaysi I, Assady S, Armaly Z, Haddad S, Haddad E, Abassi Z. Phosphodiesterase 5 inhibition protects against increased intra-abdominal pressure-induced renal dysfunction in experimental congestive heart failure. Eur J Heart Fail 2012; 14:1104-11. [PMID: 22740510 DOI: 10.1093/eurjhf/hfs102] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
AIMS Congestive heart failure (CHF) is associated with impaired renal function. Previously, we have demonstrated that rats with decompensated CHF exhibited exaggerated sensitivity to the adverse renal effects of increased increased intra-abdominal pressure (IAP) as compared with normal controls. This study tested whether phosphodiesterase 5 (PDE5) inhibition protects against the adverse renal effects of increased IAP in rats with CHF. METHODS AND RESULTS Following baseline periods, rats with compensated and decompensated CHF induced by the placement of an aorto-caval fistula (ACF), rats with myocardial infarction (MI) induced by left anterior descending (LAD) artery ligation, and sham controls were subjected to consecutive IAPs: 7, 10, or 14 mmHg. Urine flow (V), Na(+) excretion (U(Na)V), glomerular filtration rate (GFR), and renal plasma flow (RPF) were determined. The effects of pre-treatment with tadalafil on the adverse renal effects of IAP were examined in rats with decompensated CHF and MI. Elevation of IAP to 10 and 14 mmHg produced linear reductions in these parameters. Basal renal function and haemodynamics were lower in CHF rats. Decompensated CHF rats and MI rats that were subjected to 10 and 14 mmHg exhibited exaggerated declines in V, U(Na)V, GFR, and RPF. In contrast, no adverse renal effects were observed in rats with compensated CHF subjected to IAP. Pre-treatment of decompensated CHF rats and MI rats with tadalafil ameliorated the adverse renal effects of high IAP. CONCLUSION Decompensated CHF and MI rats are vulnerable to the adverse renal effects of IAP. Tadalafil abolishes IAP-induced renal dysfunction, supporting a therapeutic role for PDE5 inhibition in CHF associated with ascites.
Collapse
Affiliation(s)
- Bishara Bishara
- Department of General Surgery, Rambam Medical Center, Haifa, Israel
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Abassi ZA, Barac YD, Kostin S, Roguin A, Ovcharenko E, Awad H, Blank A, Bar-Am O, Amit T, Schaper J, Youdim M, Binah O. TVP1022 Attenuates Cardiac Remodeling and Kidney Dysfunction in Experimental Volume Overload-Induced Congestive Heart Failure. Circ Heart Fail 2011; 4:463-73. [DOI: 10.1161/circheartfailure.111.961037] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Zaid A. Abassi
- From the Department of Physiology (Z.A.A., Y.D.B., E.O., H.A., O.B.) and the Department of Pharmacology (A.B., O.B.-A., T.A., M.Y.), Rappaport Faculty of Medicine, Technion, Haifa, Israel; the Department of Cardiology (A.R.) and Research Unit (Z.A.A.), Rambam Health Campus, Haifa, Israel; and Max-Planck Institute, Core Facility of Molecular and Structural Biology, Bad Nauheim, Germany (S.K., J.S.)
| | - Yaron D. Barac
- From the Department of Physiology (Z.A.A., Y.D.B., E.O., H.A., O.B.) and the Department of Pharmacology (A.B., O.B.-A., T.A., M.Y.), Rappaport Faculty of Medicine, Technion, Haifa, Israel; the Department of Cardiology (A.R.) and Research Unit (Z.A.A.), Rambam Health Campus, Haifa, Israel; and Max-Planck Institute, Core Facility of Molecular and Structural Biology, Bad Nauheim, Germany (S.K., J.S.)
| | - Sawa Kostin
- From the Department of Physiology (Z.A.A., Y.D.B., E.O., H.A., O.B.) and the Department of Pharmacology (A.B., O.B.-A., T.A., M.Y.), Rappaport Faculty of Medicine, Technion, Haifa, Israel; the Department of Cardiology (A.R.) and Research Unit (Z.A.A.), Rambam Health Campus, Haifa, Israel; and Max-Planck Institute, Core Facility of Molecular and Structural Biology, Bad Nauheim, Germany (S.K., J.S.)
| | - Ariel Roguin
- From the Department of Physiology (Z.A.A., Y.D.B., E.O., H.A., O.B.) and the Department of Pharmacology (A.B., O.B.-A., T.A., M.Y.), Rappaport Faculty of Medicine, Technion, Haifa, Israel; the Department of Cardiology (A.R.) and Research Unit (Z.A.A.), Rambam Health Campus, Haifa, Israel; and Max-Planck Institute, Core Facility of Molecular and Structural Biology, Bad Nauheim, Germany (S.K., J.S.)
| | - Elena Ovcharenko
- From the Department of Physiology (Z.A.A., Y.D.B., E.O., H.A., O.B.) and the Department of Pharmacology (A.B., O.B.-A., T.A., M.Y.), Rappaport Faculty of Medicine, Technion, Haifa, Israel; the Department of Cardiology (A.R.) and Research Unit (Z.A.A.), Rambam Health Campus, Haifa, Israel; and Max-Planck Institute, Core Facility of Molecular and Structural Biology, Bad Nauheim, Germany (S.K., J.S.)
| | - Hoda Awad
- From the Department of Physiology (Z.A.A., Y.D.B., E.O., H.A., O.B.) and the Department of Pharmacology (A.B., O.B.-A., T.A., M.Y.), Rappaport Faculty of Medicine, Technion, Haifa, Israel; the Department of Cardiology (A.R.) and Research Unit (Z.A.A.), Rambam Health Campus, Haifa, Israel; and Max-Planck Institute, Core Facility of Molecular and Structural Biology, Bad Nauheim, Germany (S.K., J.S.)
| | - Ayelet Blank
- From the Department of Physiology (Z.A.A., Y.D.B., E.O., H.A., O.B.) and the Department of Pharmacology (A.B., O.B.-A., T.A., M.Y.), Rappaport Faculty of Medicine, Technion, Haifa, Israel; the Department of Cardiology (A.R.) and Research Unit (Z.A.A.), Rambam Health Campus, Haifa, Israel; and Max-Planck Institute, Core Facility of Molecular and Structural Biology, Bad Nauheim, Germany (S.K., J.S.)
| | - Orit Bar-Am
- From the Department of Physiology (Z.A.A., Y.D.B., E.O., H.A., O.B.) and the Department of Pharmacology (A.B., O.B.-A., T.A., M.Y.), Rappaport Faculty of Medicine, Technion, Haifa, Israel; the Department of Cardiology (A.R.) and Research Unit (Z.A.A.), Rambam Health Campus, Haifa, Israel; and Max-Planck Institute, Core Facility of Molecular and Structural Biology, Bad Nauheim, Germany (S.K., J.S.)
| | - Tamar Amit
- From the Department of Physiology (Z.A.A., Y.D.B., E.O., H.A., O.B.) and the Department of Pharmacology (A.B., O.B.-A., T.A., M.Y.), Rappaport Faculty of Medicine, Technion, Haifa, Israel; the Department of Cardiology (A.R.) and Research Unit (Z.A.A.), Rambam Health Campus, Haifa, Israel; and Max-Planck Institute, Core Facility of Molecular and Structural Biology, Bad Nauheim, Germany (S.K., J.S.)
| | - Jutta Schaper
- From the Department of Physiology (Z.A.A., Y.D.B., E.O., H.A., O.B.) and the Department of Pharmacology (A.B., O.B.-A., T.A., M.Y.), Rappaport Faculty of Medicine, Technion, Haifa, Israel; the Department of Cardiology (A.R.) and Research Unit (Z.A.A.), Rambam Health Campus, Haifa, Israel; and Max-Planck Institute, Core Facility of Molecular and Structural Biology, Bad Nauheim, Germany (S.K., J.S.)
| | - Moussa Youdim
- From the Department of Physiology (Z.A.A., Y.D.B., E.O., H.A., O.B.) and the Department of Pharmacology (A.B., O.B.-A., T.A., M.Y.), Rappaport Faculty of Medicine, Technion, Haifa, Israel; the Department of Cardiology (A.R.) and Research Unit (Z.A.A.), Rambam Health Campus, Haifa, Israel; and Max-Planck Institute, Core Facility of Molecular and Structural Biology, Bad Nauheim, Germany (S.K., J.S.)
| | - Ofer Binah
- From the Department of Physiology (Z.A.A., Y.D.B., E.O., H.A., O.B.) and the Department of Pharmacology (A.B., O.B.-A., T.A., M.Y.), Rappaport Faculty of Medicine, Technion, Haifa, Israel; the Department of Cardiology (A.R.) and Research Unit (Z.A.A.), Rambam Health Campus, Haifa, Israel; and Max-Planck Institute, Core Facility of Molecular and Structural Biology, Bad Nauheim, Germany (S.K., J.S.)
| |
Collapse
|